Salicylic acid

Description

The drug is a fast-acting wart remover liquid, designed for topical application. It is formulated to effectively target and eliminate warts. The packaging includes a visual reference labeled "FAST ACTING WART REMOVER LIQUID(2)_1.jpg," which provides additional information regarding the product's appearance and branding.

Uses and Indications

This drug is indicated for the treatment of corns and warts.

There are no teratogenic effects associated with this drug. Additionally, no nonteratogenic effects have been reported.

Dosage and Administration

The corns or warts should be washed with warm water prior to treatment. After cleansing, the inner plug must be removed from the bottle. The brush should be installed into the bottle cap, ensuring it is pressed tightly, and the cap should then be securely tightened onto the bottle.

Once the skin is dry, the cap can be opened, and the brush should be dipped into the liquid. The liquid is to be applied directly to the wart or corn. After the initial application dries and forms a mask, a second application of the liquid should be made.

This treatment should be administered topically to the affected area twice daily, once in the morning and once at night. Each application should consist of two coats of the liquid. The treatment should be continued for a duration of 2 weeks or until the skin has returned to a healthy state.

Contraindications

Use of this product is contraindicated in the following situations:

Application on damaged skin, including areas with cuts, abrasions, eczema, or sunburn, is not recommended due to the potential for increased irritation and adverse effects.

Patients with known allergies to any of the product's ingredients should avoid use to prevent allergic reactions.

The product is also contraindicated in pregnant or breastfeeding individuals, as safety during these conditions has not been established.

Warnings and Precautions

The product is intended for external use only. It is imperative to avoid contact with the eyes and to refrain from swallowing the product. Children should utilize this product only under the supervision of an adult to ensure safety.

Care should be taken to prevent the liquid from volatilizing and crystallizing; therefore, it is essential to securely tighten the cap after each use. Additionally, long-term exposure to air should be avoided to maintain the integrity of the product.

General precautions must be observed when using this product. It should not be applied to damaged skin, including areas with cuts, abrasions, eczema, or sunburn. Individuals with known allergies to any of the ingredients in this formulation should refrain from use. Furthermore, caution is advised for pregnant or breastfeeding individuals, as the safety of the product in these populations has not been established.

Patients are advised to discontinue use and consult a healthcare professional if they become pregnant or are planning to become pregnant while using this product.

Side Effects

Patients should be aware that the product is intended for external use only and must not come into contact with the eyes or be ingested. It is advised that children use the product under adult supervision to ensure safety.

In clinical practice, it is important to note that the liquid formulation can easily volatilize and crystallize; therefore, users should ensure that the cap is tightened after each use to maintain product integrity. Additionally, long-term exposure to air should be avoided during use to prevent degradation of the product.

Patients are advised to discontinue use and consult a healthcare professional if they become pregnant or are planning to become pregnant while using the product.

Drug Interactions

No drug interactions or drug and laboratory test interactions have been identified in the available data. Therefore, no specific recommendations for dosage adjustments or monitoring are necessary at this time.

Packaging & NDC

Below are the non-prescription pack sizes of Fast Acting Wart Remover. Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric patients should use this medication under the supervision of adults to ensure safety and proper administration. It is important to keep the medication out of reach of children to prevent accidental ingestion or misuse.

Geriatric Use

There is no specific information regarding the use of this medication in geriatric patients, including dosage adjustments, safety concerns, or special precautions. Healthcare providers should exercise caution when prescribing this medication to elderly patients, as individual responses may vary. Monitoring for potential adverse effects and therapeutic efficacy is recommended in this population.

Pregnancy

Pregnant patients and those who are breastfeeding should not use this product due to potential risks to fetal outcomes and infant health. If a patient becomes pregnant or is planning to become pregnant while using the product, it is advised to discontinue use immediately. The safety of this product during pregnancy and lactation has not been established, and the potential for adverse effects on the developing fetus or nursing infant remains unknown. Therefore, healthcare professionals should counsel women of childbearing potential regarding these risks and recommend alternative treatments as necessary.

Lactation

Lactating mothers should be aware of the potential implications of using this medication while breastfeeding. There is limited information available regarding the excretion of this drug in human breast milk. Therefore, healthcare professionals should carefully consider the benefits and risks when prescribing this medication to lactating mothers.

Breastfed infants may be affected by the presence of the drug in breast milk, although specific data on the effects on nursing infants are not provided. It is advisable for healthcare providers to monitor breastfed infants for any adverse effects if the mother is using this medication.

In summary, the decision to use this medication in lactating mothers should involve a thorough assessment of the potential risks to the infant versus the therapeutic benefits to the mother.

Renal Impairment

Patients with renal impairment have not been specifically addressed in the available prescribing information. There are no dosage adjustments, special monitoring requirements, or safety considerations outlined for individuals with reduced kidney function. Healthcare professionals should exercise caution and consider the lack of data when prescribing to this patient population.

Hepatic Impairment

Patients with hepatic impairment have not been specifically studied in clinical trials for this medication. Consequently, there is no information available regarding dosage adjustments, special monitoring requirements, or precautions for individuals with compromised liver function. It is recommended that healthcare providers exercise caution when prescribing this medication to patients with hepatic impairment, given the lack of data on its safety and efficacy in this population.

Overdosage

In the absence of specific details regarding overdosage for this medication (SPL code 34088-5), healthcare professionals are advised to exercise caution and adhere to general principles of management in cases of suspected overdosage.

Recommended Actions In the event of an overdosage, it is essential to seek immediate medical attention. Healthcare providers should assess the patient's clinical status and consider the need for supportive care. Monitoring vital signs and providing symptomatic treatment may be necessary.

Potential Symptoms While specific symptoms associated with overdosage are not detailed, healthcare professionals should remain vigilant for any unusual or severe reactions that may arise. Symptoms may vary based on the pharmacological profile of the medication and the individual patient's response.

Management Procedures Management of overdosage should be tailored to the individual case. Healthcare professionals are encouraged to consult established guidelines and protocols for the management of overdosage related to similar pharmacological agents. In cases where the specific antidote or treatment is known, it should be administered as per standard medical practice.

In summary, due to the lack of specific overdosage information, healthcare professionals must rely on their clinical judgment and established medical protocols to manage suspected cases effectively.

Nonclinical Toxicology

The available nonclinical data indicate potential teratogenic effects associated with the use of the product during pregnancy or breastfeeding. It is advised that individuals who are pregnant or breastfeeding should avoid using the product due to these concerns.

Additionally, there are noted non-teratogenic effects if an individual becomes pregnant or is planning to become pregnant while using the product. This suggests that while the product may not directly cause teratogenic effects in all cases, caution is warranted for those in reproductive stages.

No further relevant information regarding nonclinical toxicology or animal pharmacology and toxicology has been provided.

Postmarketing Experience

No postmarketing experience details are available in the insert text.

Patient Counseling

Healthcare providers should advise patients to keep the product out of reach of children to prevent accidental ingestion or misuse. It is important to instruct patients not to apply the product on damaged skin, including areas with cuts, abrasions, eczema, or sunburn, as this may exacerbate irritation or lead to adverse effects.

Patients should be informed of the importance of reviewing the ingredient list and to avoid using the product if they have a known allergy to any of its components. Additionally, healthcare providers should counsel patients against using the product during pregnancy or while breastfeeding, emphasizing the potential risks involved.

If a patient becomes pregnant or is planning to become pregnant while using the product, they should be advised to discontinue use immediately and consult their healthcare provider for further guidance.

Storage and Handling

The product is supplied in various package configurations, with specific NDC numbers available for identification. Currently, there are no specified storage or handling conditions outlined in the provided information. Therefore, it is recommended that healthcare professionals refer to the product's official labeling or consult with the manufacturer for any additional details regarding storage and handling requirements.

Additional Clinical Information

No further data are available.

Drug Information (PDF)

This file contains official product information for Fast Acting Wart Remover, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)